Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Indicators

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    186 result(s) found for: Indicators. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004296-35 Sponsor Protocol Number: RGHT000203 Start Date*: 2007-10-18
    Sponsor Name:The Royal Group of Hospitals, Belfast Health and Social Care Trust [...]
    1. The Royal Group of Hospitals, Belfast Health and Social Care Trust
    2. Queen's University Belfast
    Full Title: An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment
    Medical condition: The proposed study will investigate early indicators of cardiovascular disease and diabetes in healthy, obese men without a family history of diabetes and whether these are changed by treatment wit...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005203-18 Sponsor Protocol Number: 110551 Start Date*: 2008-06-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous mela...
    Medical condition: MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000586-19 Sponsor Protocol Number: 307971 Start Date*: 2005-07-25
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC)
    Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000760-18 Sponsor Protocol Number: 13.034 Start Date*: 2014-11-24
    Sponsor Name:Prof. Peter Licht
    Full Title: Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study.
    Medical condition: Cancer pulmones
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003823-31 Sponsor Protocol Number: AG348-C-006 Start Date*: 2019-04-08
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) PT (Completed) ES (Completed) DK (Completed) NL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000447-27 Sponsor Protocol Number: USKH_VL1 Start Date*: 2012-07-25
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery
    Medical condition: Pharmacokinetic trial in patients, with a good general condition before standard abdominal surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-012340-16 Sponsor Protocol Number: EPU P49 Start Date*: 2009-07-20
    Sponsor Name:Maastricht University
    Full Title: Effects of morning versus evening dose of hydroxyzine 50 mg on cognition in healthy subjects
    Medical condition: To assess the morning versus evening dose effect of hydroxyzine 50 mg on cognition in healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003229-31 Sponsor Protocol Number: CCRG21-001 Start Date*: 2022-12-05
    Sponsor Name:Antwerp University Hospital
    Full Title: Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma
    Medical condition: Malignant pleural mesothelioma, epithelioid subtype (stage I-IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023325-37 Sponsor Protocol Number: CRO1656 Start Date*: 2011-01-25
    Sponsor Name:Imperial College
    Full Title: UMPIRE Trial sub-study - Polypill Effects on Sub Clinical Atherosclerosis (PESCA): A randomised controlled trial of a cardiovascular polypill treatment strategy compared with usual care on carotid ...
    Medical condition: Cardiovascular disease subjects either with established disease or at high risk
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004226-82 Sponsor Protocol Number: 10077 Start Date*: 2006-09-07
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHARMACODYNAMIC STUDY OF ORAL MIRTOSELECT IN PATIENTS WITH SUSPECTED COLORECTAL DISEASE
    Medical condition: Patients with operable colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061451 Colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002470-42 Sponsor Protocol Number: FluSHED-2 Start Date*: 2018-08-30
    Sponsor Name:Imperial College London JRC Office
    Full Title: Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study
    Medical condition: Prevention of influenza infection through immunisation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005401-28 Sponsor Protocol Number: AOI2021ME_PICKERING Start Date*: 2022-01-26
    Sponsor Name:University Hospital of Clermont-Ferrand
    Full Title: Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial
    Medical condition: postmenopausal osteoporosis
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000783-42 Sponsor Protocol Number: SDX-PL/001/2016 Start Date*: 2016-09-19
    Sponsor Name:Alfa Wassermann Polska Sp. z o.o.
    Full Title: A phase 3, prospective, open, pilot, monocentric study to evaluate the effect of sulodexide administered at registered dose on morphology and functional properties of the venous endothelium in pati...
    Medical condition: chronic venous insufficiency
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066682 Chronic venous insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023861-23 Sponsor Protocol Number: EPU P61 Start Date*: 2011-01-31
    Sponsor Name:Maastricht University
    Full Title: The effect of P-glycoprotein transport inhibition on brainmechanisms of sedation and cognitive impairment following antihistamines in healthy volunteers
    Medical condition: To assess the effects of inhibition of the P-glycoproteine transporter (by verapamil 120 mg) on cetirizine 15 mg in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003177-32 Sponsor Protocol Number: IBMR31 Start Date*: 2022-11-17
    Sponsor Name:Instituto Bernabeu
    Full Title: Continuous ovarian stimulation in DUOSTIM cycles.
    Medical condition: Patients with predictive indicators of low ovarian response and who undergo double ovarian stimulation (DUOSTIM).
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000484-13 Sponsor Protocol Number: AG-348-C-003 Start Date*: 2015-07-10
    Sponsor Name:Agios Pharmaceuticals Inc
    Full Title: A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004686-41 Sponsor Protocol Number: IBA1160 Start Date*: 2020-12-02
    Sponsor Name:Helsinn Healthcare SA
    Full Title: MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
    Medical condition: Patients treated with IV moderately emetogenic chemotherapy and at high risk of chemotherapy induced nausea and vomiting (CINV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CZ (Completed) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003803-22 Sponsor Protocol Number: AG348-C-007 Start Date*: 2018-06-27
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) GB (Completed) IE (Completed) IT (Completed) ES (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-001223-13 Sponsor Protocol Number: V58_31 Start Date*: 2014-12-03
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Ch...
    Medical condition: Prophylaxis: Influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004696-24 Sponsor Protocol Number: ANESBUPI_1/2014 Start Date*: 2016-02-29
    Sponsor Name:HOSPITAL UNIVERSITARIO LA PAZ, SERVICIO DE ANESTESIA
    Full Title: Breakthrough pain incidence in pregnant women comparing two Epidural analgesia shemes added to a continuous infusion (bowling planned indicators and analgesia epidural patient controlled): double-b...
    Medical condition: EPIDURAL ANALGESIA IN PARTURIENTS
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:41:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA